Family CFO’s Moderna MRNA Stock Holding History

Family CFO’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10	Closed	-$1.03K	–	78
2023 Q3	$1.03K	Buy	+10	New	+$1.11K	﹤0.01%	77

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Family CFO's MRNA Position: Q4 2023 in Review

Family CFO sold out of Moderna (MRNA) in Q4 2023, closing a stake of 10 shares — an estimated $1.03K sold.

Family CFO first reported a position in MRNA in Q3 2023 and held it in 1 quarter. The position peaked at $1.03K in Q3 2023. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

Family CFO reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
Family CFO sold 10 Moderna shares in Q4 2023, an estimated $1.03K.
Family CFO first reported a position in Moderna in Q3 2023 and held it in 1 quarter.
Family CFO's Moderna position peaked at $1.03K in Q3 2023.
884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Family CFO's 13F filing for Q4 2023, filed 31 Jan 2024.